181 related articles for article (PubMed ID: 27609275)
1. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
Hong Y; Li HF; Skeie GO; Romi F; Hao HJ; Zhang X; Gao X; Owe JF; Gilhus NE
J Neuroimmunol; 2016 Sep; 298():51-7. PubMed ID: 27609275
[TBL] [Abstract][Full Text] [Related]
2. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation.
Nagappa M; Mahadevan A; Gangadhar Y; Patil SA; Bokolia S; Bindu PS; Sinha S; Taly AB
Acta Neurol Scand; 2019 May; 139(5):428-437. PubMed ID: 30693486
[TBL] [Abstract][Full Text] [Related]
4. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis.
Shelton GD; Skeie GO; Kass PH; Aarli JA
Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151
[TBL] [Abstract][Full Text] [Related]
5. Muscle autoantibodies in subgroups of myasthenia gravis patients.
Romi F; Skeie GO; Aarli JA; Gilhus NE
J Neurol; 2000 May; 247(5):369-75. PubMed ID: 10896269
[TBL] [Abstract][Full Text] [Related]
6. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis.
Wang R; Li J; Wang M; Hao H; Chen X; Li R; Zhu X
Br J Dermatol; 2015 Apr; 172(4):968-75. PubMed ID: 25388377
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
[TBL] [Abstract][Full Text] [Related]
9. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
[TBL] [Abstract][Full Text] [Related]
10. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules.
Romi F; Bø L; Skeie GO; Myking A; Aarli JA; Gilhus NE
J Neuroimmunol; 2002 Jul; 128(1-2):82-9. PubMed ID: 12098514
[TBL] [Abstract][Full Text] [Related]
11. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum.
Skeie GO; Lunde PK; Sejersted OM; Mygland A; Aarli JA; Gilhus NE
Muscle Nerve; 1998 Mar; 21(3):329-35. PubMed ID: 9486861
[TBL] [Abstract][Full Text] [Related]
12. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes.
Skeie GO; Pandey JP; Aarli JA; Gilhus NE
Autoimmunity; 1997; 26(2):111-6. PubMed ID: 9546812
[TBL] [Abstract][Full Text] [Related]
13. Titin and ryanodine receptor antibodies in myasthenia gravis.
Skeie GO; Aarli JA; Gilhus NE
Acta Neurol Scand Suppl; 2006; 183():19-23. PubMed ID: 16637922
[TBL] [Abstract][Full Text] [Related]
14. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations.
Romi F; Skeie GO; Vedeler C; Aarli JA; Zorzato F; Gilhus NE
J Neuroimmunol; 2000 Nov; 111(1-2):169-76. PubMed ID: 11063835
[TBL] [Abstract][Full Text] [Related]
15. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
Hong Y; Skeie GO; Zisimopoulou P; Karagiorgou K; Tzartos SJ; Gao X; Yue YX; Romi F; Zhang X; Li HF; Gilhus NE
J Neurol; 2017 May; 264(5):955-962. PubMed ID: 28364296
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
17. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
Cordts I; Bodart N; Hartmann K; Karagiorgou K; Tzartos JS; Mei L; Reimann J; Van Damme P; Rivner MH; Vigneron A; Weis J; Schulz JB; Tzartos SJ; Claeys KG
J Neurol; 2017 Jun; 264(6):1193-1203. PubMed ID: 28516329
[TBL] [Abstract][Full Text] [Related]
18. Multiple antibody detection in 'seronegative' myasthenia gravis patients.
Hong Y; Zisimopoulou P; Trakas N; Karagiorgou K; Stergiou C; Skeie GO; Hao HJ; Gao X; Owe JF; Zhang X; Yue YX; Romi F; Wang Q; Li HF; Gilhus NE; Tzartos SJ
Eur J Neurol; 2017 Jun; 24(6):844-850. PubMed ID: 28470860
[TBL] [Abstract][Full Text] [Related]
19. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.
Mygland A; Aarli JA; Matre R; Gilhus NE
J Neurol Neurosurg Psychiatry; 1994 Jul; 57(7):843-6. PubMed ID: 8021674
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features.
Romi F; Aarli JA; Gilhus NE
Eur J Neurol; 2007 Jun; 14(6):617-20. PubMed ID: 17539937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]